The Global Enteral Syringe Market size is expected to reach $556.9 million by 2031, rising at a market growth of 5.1% CAGR during the forecast period.
The prevalence of chronic diseases, such as cancer and cardiovascular conditions, is on the rise in the Asia-Pacific region. These conditions often require enteral feeding, increasing the demand for these syringes. Patients with chronic illnesses may need long-term nutritional support, which can be effectively managed using these syringes. Consequently, the Asia Pacific region would acquire nearly 30% of the total market share by 2031.
Adopting nutritional support therapy emphasizes personalized care tailored to individual patient needs. In addition, updated clinical guidelines and protocols now commonly include recommendations for nutritional support therapy as a standard practice for managing patients with specific health conditions. Hence, the increasing adoption of nutritional support therapy is driving the market’s growth.
Additionally, Older adults frequently experience health conditions that necessitate specialized nutritional support. Conditions such as malnutrition, dysphagia (difficulty swallowing), and chronic illnesses often require enteral feeding solutions. Additionally, chronic diseases like diabetes, heart disease, and cancer are more common among the elderly population. Thus, the growing aging population is propelling the growth of the market.
However, Healthcare facilities, particularly those operating under tight budget constraints, may struggle to justify the expenditure on advanced syringes. Patients, especially those in lower-income brackets or regions with limited healthcare funding, may have restricted access to advanced syringes due to their high cost. In conclusion, the high cost of advanced syringes hampers the market’s growth.
Moreover, the postponement of elective medical procedures and treatments during the pandemic decreased the need for these syringes in certain healthcare settings. The overwhelming pressure on healthcare facilities due to the COVID-19 crisis disrupted routine care and management of patients requiring enteral feeding. Major industry events, trade shows, and conferences were cancelled or held virtually, limiting networking and market growth opportunities. Thus, the COVID-19 had a negative impact on the market.
The prevalence of chronic diseases, such as cancer and cardiovascular conditions, is on the rise in the Asia-Pacific region. These conditions often require enteral feeding, increasing the demand for these syringes. Patients with chronic illnesses may need long-term nutritional support, which can be effectively managed using these syringes. Consequently, the Asia Pacific region would acquire nearly 30% of the total market share by 2031.
Adopting nutritional support therapy emphasizes personalized care tailored to individual patient needs. In addition, updated clinical guidelines and protocols now commonly include recommendations for nutritional support therapy as a standard practice for managing patients with specific health conditions. Hence, the increasing adoption of nutritional support therapy is driving the market’s growth.
Additionally, Older adults frequently experience health conditions that necessitate specialized nutritional support. Conditions such as malnutrition, dysphagia (difficulty swallowing), and chronic illnesses often require enteral feeding solutions. Additionally, chronic diseases like diabetes, heart disease, and cancer are more common among the elderly population. Thus, the growing aging population is propelling the growth of the market.
However, Healthcare facilities, particularly those operating under tight budget constraints, may struggle to justify the expenditure on advanced syringes. Patients, especially those in lower-income brackets or regions with limited healthcare funding, may have restricted access to advanced syringes due to their high cost. In conclusion, the high cost of advanced syringes hampers the market’s growth.
Moreover, the postponement of elective medical procedures and treatments during the pandemic decreased the need for these syringes in certain healthcare settings. The overwhelming pressure on healthcare facilities due to the COVID-19 crisis disrupted routine care and management of patients requiring enteral feeding. Major industry events, trade shows, and conferences were cancelled or held virtually, limiting networking and market growth opportunities. Thus, the COVID-19 had a negative impact on the market.
Driving and Restraining Factors
Drivers
- Increasing adoption of nutritional support therapy
- Growing aging population globally
- Rising prevalence of chronic diseases worldwide
Restraints
- High cost of advanced enteral syringes
- Risk of product recalls and safety concerns
Opportunities
- Expansion of healthcare infrastructure
- Rising incidence of paediatric conditions
Challenges
- Variability in patient needs and preferences
- High competition from alternative feeding methods
Age Group Outlook
On the basis of age group, the market is segmented into adults and paediatrics. In 2023, the paediatrics segment attained 23% revenue share in the market. Advances in medical care have significantly improved the survival rates of preterm infants and children with severe health conditions, many of whom require enteral feeding.End User Outlook
By end user, the market is divided into hospitals, ambulatory surgical centres, and homecare. The homecare segment procured a 13% revenue share in the market in 2023. As the global population ages, more elderly individuals require long-term care, including enteral feeding, which can be effectively managed at home using these syringes.Type Outlook
Based on type, the market is divided into reusable and disposable. The reusable segment procured 37% revenue share in the market in 2023. Although reusable syringes require an initial investment, they can be more cost-effective over time than disposable syringes. For healthcare facilities with high usage rates, the cumulative cost of disposables can be significantly higher.Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed a 35% revenue share in the market in 2022. North America boasts a sophisticated healthcare system with numerous hospitals, clinics, and long-term care facilities equipped with advanced medical technologies, including these syringes.List of Key Companies Profiled
- Boston Scientific Corporation
- Nestlé S.A.
- Fresenius SE & Co. KGaA
- Becton, Dickinson and Company
- Braun Melsungen AG
- Cardinal Health, Inc.
- Moog Inc.
- Cook Medical, Inc.(Cook Group)
- Thermo Fisher Scientific Inc.
- Medela AG
Market Report Segmentation
By Age Group
- Adults
- Pediatrics
By End User
- Hospitals
- Ambulatory Surgical Centers
- Homecare
By Type
- Disposable
- Reusable
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global Enteral Syringe Market by Age Group
Chapter 5. Global Enteral Syringe Market by End User
Chapter 6. Global Enteral Syringe Market by Type
Chapter 7. Global Enteral Syringe Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- Nestlé S.A.
- Fresenius SE & Co. KGaA
- Becton, Dickinson and Company
- B. Braun Melsungen AG
- Cardinal Health, Inc.
- Moog Inc.
- Cook Medical, Inc.(Cook Group)
- Thermo Fisher Scientific Inc.
- Medela AG
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 226 |
| Published | August 2024 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 378.6 Million |
| Forecasted Market Value ( USD | $ 556.9 Million |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
